Metastatic disease causes over 90% of cancer deaths, but targeted therapies are lacking due to limited understanding of its molecular mechanisms. Both genetic (SNVs and chromosome instability) and non-genetic (transcriptional reprogramming) factors contribute to metastasis, with unknown links between chromosome instability, transcriptional reprogramming, and metastasis. This project aims to investigate whether chromosome rearrangements and SNVs at GRHL2 enhancers disrupt genome architecture, weakening epithelial transcriptional programs and promoting metastatic phenotypes. Using advanced bioinformatic tools, the candidate will reconstruct GRHL2-enhancer interactions, identify relevant genes, and assess clinical significance in large patient cohorts, potentially impacting cancer research and personalized oncology.
Requirements:
- PhD in bioinformatics, computational biology or similar
- Programming skills in R and/or python
- Experience in ChIPseq and bulk RNAseq data analysis and interpretation
- Experience in Hi-C and HiChIP data analysis and interpretation
- Experience in small and structural variant analysis
- Proficient in Unix system
Nice to have:
- Experience in scRNAseq data analysis
- Experience with pipeline manager (NextFlow, SnakeMake etc..)
- Experience with HPC
Working environment:
The European Institute of Oncology (IEO) is one of the leading research institutes in Italy. IEO operates as a Comprehensive Cancer Center, linking fundamental and applied research to clinical activities, patient care and clinical trials. The Department of Experimental Oncology (DEO) hosts ~250 scientists working in 20 independent research groups and units. DEO is located within a scientific campus together with two other partner institutions: the FIRC Institute of Molecular Oncology (IFOM) and the Italian Institute of Technology (IIT). The IEO is one of the 13 members of the EU-LIFE alliance to promote excellence in life sciences in Europe. IEO is an equal opportunity employer committed to excellence through diversity.
Further info:
Write to [email protected], [email protected]
Posted on 8th July 2024